Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diltiazem hydrochloride 60mg - film coated tablet - 60 mg - active: diltiazem hydrochloride 60mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate methyl hydroxybenzoate microcrystalline cellulose opadry quinoline yellow sunset yellow fcf - patients with moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - diltiazem hydrochloride 30mg;  ;  ;  ;   - film coated tablet - 30 mg - active: diltiazem hydrochloride 30mg         excipient: aluminium hydroxide gel hydrogenated castor oil lactose monohydrate magnesium stearate methacrylic acid copolymer opadry white y-1r-7000b purified talc

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - diltiazem hydrochloride 60mg;  ;  ;  ;   - film coated tablet - 60 mg - active: diltiazem hydrochloride 60mg         excipient: aluminium hydroxide gel hydrogenated castor oil lactose monohydrate magnesium stearate methacrylic acid copolymer opadry white y-1r-7000b purified talc

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: purified talc; sodium lauryl sulfate; methacrylic acid copolymer; povidone; simethicone; diethyl phthalate; tributyl acetylcitrate; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: ethylcellulose; simethicone; purified talc; castor oil; tributyl acetylcitrate; white beeswax; methacrylic acid copolymer; titanium dioxide; gelatin; colloidal anhydrous silica; brilliant blue fcf; stearic acid; fumaric acid; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 180 mg - capsule, modified release - excipient ingredients: fumaric acid; gelatin; methacrylic acid copolymer; brilliant blue fcf; white beeswax; stearic acid; colloidal anhydrous silica; simethicone; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; purified talc; maize starch; sucrose - diltiazem sandoz cd is indicated for the treatment of hypertension. diltiazem sandoz cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: methacrylic acid copolymer; diethyl phthalate; sodium lauryl sulfate; purified talc; povidone; simethicone; tributyl acetylcitrate; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 360 mg - capsule, modified release - excipient ingredients: purified talc; methacrylic acid copolymer; povidone; tributyl acetylcitrate; sodium lauryl sulfate; diethyl phthalate; simethicone; maize starch; sucrose; titanium dioxide; brilliant blue fcf; potable water; gelatin; silicon dioxide - cardizem cd is indicated for the treatment of hypertension. cardizem cd is also indicated for the management of chronic stable angina (effort-associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina has not been substantiated, use of this formulation for these indications is not recommended.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: magnesium stearate; methyl hydroxybenzoate; quinoline yellow; sunset yellow fcf; hypromellose; colloidal anhydrous silica; lactose monohydrate; microcrystalline cellulose; hyprolose; macrogol 3350; macrogol 400 - patients with moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride, quantity: 240 mg - capsule, modified release - excipient ingredients: gelatin; brilliant blue fcf; ethylcellulose; titanium dioxide; tributyl acetylcitrate; castor oil; methacrylic acid copolymer; stearic acid; purified talc; fumaric acid; simethicone; white beeswax; colloidal anhydrous silica; maize starch; sucrose - vasocardol cd is indicated for the treatment of hypertension. vasocardol cd is also indicated for the management of chronic stable angina (effort associated angina) where there is no evidence of vasospastic or unstable angina. since the safety and efficacy of cd capsules in the management of unstable or vasospastic angina have not been substantiated, use of this formulation for these indications is not recommended